Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 2 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.


Player Avatar jcov1337 (85.06) Submitted: 12/3/2012 1:32:49 PM : Outperform Start Price: $4.47 FOLD Score: -88.03

Positive data from the 6 month Phase III trial of Amigal as well as a positive readout from its Phase II study of AT-2220 will add substantial value to the company and boost the PPS. My target for after data is $9.00.

Featured Broker Partners